At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
|Videos|July 8, 2014
From the Early Days in Oncology to Now
Author(s)James O. Armitage, MD
In this interview Dr. Armitage discusses his early career and what led him to specialize in the treatment of lymphoma, and shares his thoughts on the future of cancer treatment.
Advertisement
At the ASCO 2014 Annual Meeting, James O. Armitage, MD, professor in the department of internal medicine at the University of Nebraska Medical Center and editor in chief of ONCOLOGY, received the Special Recognition Award to celebrate his accomplishments in the fields of oncology and hematology. In this interview, Dr. Armitage discusses his early career and what led him to specialize in the treatment of lymphoma, and shares his thoughts on the biggest present-day issues in oncology and the future of cancer treatment.
Advertisement
Related to this article
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.
At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
4
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
5